FDAnews Drug Daily Bulletin

METHYLGENE ANNOUNCES FIRST QUARTER 2006 RESULTS

May 8, 2006
A A

MethylGene Inc, a biopharmaceutical company, today announced operational and financial results for the first quarter ended March 31, 2006. Highlights: Signed a research, development and commercialization agreement with Pharmion Corporation, a deal worth potentially up to US$272 million, for MethylGene's oncology HDAC inhibitors, including MGCD0103, for North America, Europe and other territories. CCN Matthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=593063)